@article{10.11648/j.ajim.20221001.13,
  author = {Leopoldo Ferrante and Walter Filippelli and Luigi Petrillo and Giovanni Castaldo and Alessio Sullo and Gaetano Motta and Anna D’Alessio},
  title = {Neuroleptic Therapy as an Antitumor Protective Factor in Schizophrenic Patients with Polysindromic Framework: Observational Study},
  journal = {American Journal of Internal Medicine},
  volume = {10},
  number = {1},
  pages = {13-19},
  doi = {10.11648/j.ajim.20221001.13},
  url = {https://doi.org/10.11648/j.ajim.20221001.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20221001.13},
  abstract = {Schizophrenia is one of the psychiatric pathologies that involves the highest family, social and economic costs. The symptomatology affects various areas of an individual's life that include thought, emotions and the social aspect, with a remarkably long and variable course of the pathology, with subjects who may be chronically ill and others, instead, subjected to exacerbations and remissions. Despite the high efforts and advances in the field of pharmacology and psychotherapy treatments, to date, a real 'restitutio ad integrum' has not yet been reached. The drug therapy par excellence used to restore the biochemical balance is given by typical and atypical neuroleptics. The use of these drugs has led to widespread debates on the relationship between schizophrenia and cancer, as they appear to have an anti-tumor protective factor. In the Villa dei Pini Neuripsychiatric facility in Avellino, in a period between 2006 and 2016, an observational study was carried out on a population of patients diagnosed with schizophrenia (DSM-IV. TR). Each hospitalized subject, both new admission and re-entry, underwent clinical interview and a complete blood count with a chest x-ray. 4962 records of patients with Schizophrenic Psychosis have been taken into consideration, belonging to 888 patients (660 M and 228F) who had a history of being heavy smokers (about 90%) with concomitant depressive symptomatology (about 70%), hypertension (65%) and hearing loss (55%); the patients have been re-evaluated over time: at each re-entry into the clinic a complete blood count was performed with leukocyte formula, VES and PCR, and a Thoracic X-ray (the average number of patients returned to the clinic and 6 for patients 4 for female patients); some others were contacted by telephone interview. All the patients taken into consideration had at least one neuroleptic drug in therapy during the hospital stay. Among these patients, re-evaluated over time at each re-entry into the clinic or reached by telephone interview, about 2% (16 patients) developed lung K; the incidence is greater in patients with more than one comorbidity (diabetes, hypertension with familiarity due to oncological pathology). The data collected seem to go in the direction of the observations made by the various authors over time, that is the role of neuroleptic drugs as a protective factor in the onset and development of cancer, especially in the lung. To date the schizophrenia and cancer controversy is still open and in a phase of strong interest.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Neuroleptic Therapy as an Antitumor Protective Factor in Schizophrenic Patients with Polysindromic Framework: Observational Study
AU  - Leopoldo Ferrante
AU  - Walter Filippelli
AU  - Luigi Petrillo
AU  - Giovanni Castaldo
AU  - Alessio Sullo
AU  - Gaetano Motta
AU  - Anna D’Alessio
Y1  - 2022/01/28
PY  - 2022
N1  - https://doi.org/10.11648/j.ajim.20221001.13
DO  - 10.11648/j.ajim.20221001.13
T2  - American Journal of Internal Medicine
JF  - American Journal of Internal Medicine
JO  - American Journal of Internal Medicine
SP  - 13
EP  - 19
PB  - Science Publishing Group
SN  - 2330-4324
UR  - https://doi.org/10.11648/j.ajim.20221001.13
AB  - Schizophrenia is one of the psychiatric pathologies that involves the highest family, social and economic costs. The symptomatology affects various areas of an individual's life that include thought, emotions and the social aspect, with a remarkably long and variable course of the pathology, with subjects who may be chronically ill and others, instead, subjected to exacerbations and remissions. Despite the high efforts and advances in the field of pharmacology and psychotherapy treatments, to date, a real 'restitutio ad integrum' has not yet been reached. The drug therapy par excellence used to restore the biochemical balance is given by typical and atypical neuroleptics. The use of these drugs has led to widespread debates on the relationship between schizophrenia and cancer, as they appear to have an anti-tumor protective factor. In the Villa dei Pini Neuripsychiatric facility in Avellino, in a period between 2006 and 2016, an observational study was carried out on a population of patients diagnosed with schizophrenia (DSM-IV. TR). Each hospitalized subject, both new admission and re-entry, underwent clinical interview and a complete blood count with a chest x-ray. 4962 records of patients with Schizophrenic Psychosis have been taken into consideration, belonging to 888 patients (660 M and 228F) who had a history of being heavy smokers (about 90%) with concomitant depressive symptomatology (about 70%), hypertension (65%) and hearing loss (55%); the patients have been re-evaluated over time: at each re-entry into the clinic a complete blood count was performed with leukocyte formula, VES and PCR, and a Thoracic X-ray (the average number of patients returned to the clinic and 6 for patients 4 for female patients); some others were contacted by telephone interview. All the patients taken into consideration had at least one neuroleptic drug in therapy during the hospital stay. Among these patients, re-evaluated over time at each re-entry into the clinic or reached by telephone interview, about 2% (16 patients) developed lung K; the incidence is greater in patients with more than one comorbidity (diabetes, hypertension with familiarity due to oncological pathology). The data collected seem to go in the direction of the observations made by the various authors over time, that is the role of neuroleptic drugs as a protective factor in the onset and development of cancer, especially in the lung. To date the schizophrenia and cancer controversy is still open and in a phase of strong interest.
VL  - 10
IS  - 1
ER  - 

Copy | Download